1. Scrip
  2. >>Business

Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

 
• By Emily Hayes

Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.

With indications in melanoma, second-line lung cancer and second-line kidney cancer under its belt, the PD-1 inhibitor had sales of about $1bn in 2015, at the forefront of successful oncology launches.

In the first quarter, Opdivo brought in $704m in sales, Bristol reported April 28. And the product continues to grow...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout

 
• By Andrew McConaghie

Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.

Sanofi Flies The Flag For France

 
• By Kevin Grogan

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?

 
• By Alaric DeArment

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

Finance Watch: Lilly Toes The $1 Trillion Valuation Line

 
• By Mandy Jackson

Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.

More from Scrip

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.